Qualigen Therapeutics

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces data from the Company's four posters regarding its' lead program, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 held April 14-19 in Orlando, FL.

Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL

In V ivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type

Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL

CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the United States Patent and Trademarks Office (USPTO) has granted the Company patent number 11,560,380 for QN-302, its lead oncology investigational drug candidate, a small molecule selective transcription inhibitor with strong binding affinity to G4 complexes prevalent in cancer cells being investigated for solid tumors, including pancreatic cancer.

Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office

CARLSBAD, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the Company will be presenting five posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 to be held April 14-19 in Orlando, FL. The AACR Conference is a focal point of the cancer research community, where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine.

Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023

Data demonstrates potential anti-RAS activity with Qualigen's novel RAS small molecule in both pancreatic and breast cancer in vivo models

Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference

S100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models

Data on Potential Biomarker for Qualigen Therapeutics' Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today issued the following letter to its stockholders:

Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders

CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the initiation of Good Laboratory Practice (GLP) toxicology studies of its lead oncology program, QN-302, a G4-selective transcription inhibitor currently in development for the treatment of G4 (G-Quadruplex) expressing solid tumors, including pancreatic cancer.

Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302

CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces the promotion of Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications.

Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications

CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead drug candidate, QN-302, for the indication of Pancreatic Cancer. QN-302 is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer

CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today shares an update on its majority-owned subsidiary, NanoSynex Ltd. (“NanoSynex”), the progress made during 2022, and objectives for 2023 concerning the commercialization plans for its innovative rapid Antimicrobial Susceptibility Test (AST).

Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform

CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The letter noted that as a result of the closing bid price of the Company's common stock having been at least $1.00 per share for a minimum of 10 consecutive business days, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that it has received feedback from the FDA following a pre-Investigational New Drug (pre-IND) interaction regarding the development pathway to a Phase 1 clinical trial of QN-302 for the treatment of G4-targeted advanced solid tumors. The purpose of the pre-IND interaction was to inform the proposed content of the Company's IND application and request guidance from the Division on specific questions prior to submission of the IND application. The FDA's response provides Qualigen with clear guidance for formally submitting an IND application for QN-302 after accounting for the agency's comments and suggestions.

Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors

Action to comply with continued listing requirements for Nasdaq Capital Market

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split

Q3 2022 FastPack ® sales increased approximately 25% year-over-year Company continues to execute on and advance core therapeutic programs

Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Fou r th RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models

Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute

CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Amy Broidrick, President and Chief Strategy Officer, and Tariq Arshad, MD, Chief Medical Officer, will present a corporate overview at the LD Micro Main Event XV. The conference is being held on October 25 – 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Qualigen Therapeutics to Present at LD Micro Main Event XV

Posters include data regarding 1) m ode of action , and 2) preclinical toxicology

Qualigen Therapeutics Presents Data on QN-302 at AACR's Pancreatic Cancer Meeting

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has formed a Scientific Advisory Board (SAB) in support of the development of its lead therapeutic candidate QN-302 for the potential treatment of pancreatic cancer and other G4-prevalent solid tumors.

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

Q2 2022 FastPack ® Sales increased approximately 28 %, and gross profit on product sales was up 64% year-over-year from Q2 2021

Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has completed its in vivo efficacy analysis of QN-247 in solid tumors. Data demonstrates robust efficacy and no safety signals in a triple negative breast cancer (TNBC) model.

Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model

CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its partnership with China-based Hande Sciences (“Hande”) to conduct manufacturing scale-up activities to support the Company's IND-enabling good laboratory practice (GLP) studies for its lead therapeutic program, QN-302.

Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302

CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Center.

Qualigen Therapeutics to Present at BIO International Convention

A P otential T reatment for Pancreatic Cancer in A ddition to O ther T umors of H igh U nmet C linical N eed

Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

Transaction expected to significantly advance commercial readiness of Nano S ynex' s innovative diagnostic s technology platform focused on the $30+ Billion global infectious disease testing market

News for Qualigen Therapeutics Stock (QLGN)